Shenyang Xingqi Pharmaceutical Co.,Ltd. (SHE:300573)
China · Delayed Price · Currency is CNY 38.52
-1.23 (-3.09%)
Aug 24, 2026, 3:04 PM CST
SHE:300573 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 13,764 | 17,322 | 12,229 | 22,715 | 11,076 | 11,263 | |
Market Cap Growth | -16.24% | 41.64% | -46.16% | 105.08% | -1.66% | 47.96% |
Enterprise Value | 13,271 | 17,076 | 11,973 | 22,352 | 10,579 | 11,226 |
Last Close Price | 38.52 | 47.74 | 33.07 | 60.72 | 29.47 | 31.94 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 18.13 | 24.89 | 36.17 | 94.63 | 52.33 | 57.85 |
Forward PE | - | 24.68 | 24.68 | 62.66 | 24.48 | - |
PS Ratio | 5.25 | 7.01 | 6.29 | 15.48 | 8.86 | 10.96 |
PB Ratio | 6.30 | 8.76 | 7.68 | 13.44 | 7.14 | 8.38 |
P/TBV Ratio | 7.00 | 9.87 | 8.38 | 14.09 | 7.27 | 8.52 |
P/FCF Ratio | 27.13 | 35.87 | 56.03 | 408.51 | - | 53.15 |
P/OCF Ratio | 17.85 | 22.99 | 29.33 | 71.53 | 38.69 | 36.69 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.07 | 6.91 | 6.16 | 15.23 | 8.46 | 10.92 |
EV/EBITDA Ratio | 13.73 | 18.73 | 23.83 | 65.68 | 35.59 | 37.73 |
EV/EBIT Ratio | 15.53 | 21.07 | 29.32 | 85.99 | 45.76 | 46.72 |
EV/FCF Ratio | 26.15 | 35.36 | 54.85 | 401.97 | - | 52.98 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.04 | 0.04 | 0.14 | 0.05 | 0.01 | 0.08 |
Debt / EBITDA Ratio | 0.08 | 0.09 | 0.42 | 0.23 | 0.05 | 0.36 |
Debt / FCF Ratio | 0.16 | 0.17 | 0.99 | 1.42 | - | 0.53 |
Net Debt / Equity Ratio | -0.23 | -0.16 | -0.10 | -0.24 | -0.32 | -0.43 |
Net Debt / EBITDA Ratio | -0.51 | -0.34 | -0.31 | -1.18 | -1.69 | -1.93 |
Net Debt / FCF Ratio | -0.97 | -0.64 | -0.71 | -7.22 | 38.70 | -2.71 |
Asset Turnover | 1.04 | 1.06 | 0.94 | 0.77 | 0.72 | 0.78 |
Inventory Turnover | 2.59 | 2.79 | 2.93 | 2.64 | 2.52 | 2.85 |
Quick Ratio | 1.76 | 1.44 | 1.41 | 2.83 | 4.69 | 3.23 |
Current Ratio | 2.23 | 1.86 | 1.80 | 3.48 | 5.68 | 3.69 |
Return on Equity (ROE) | 38.51% | 38.97% | 20.59% | 14.81% | 14.62% | 20.52% |
Return on Assets (ROA) | 21.17% | 21.71% | 12.30% | 8.54% | 8.33% | 11.33% |
Return on Invested Capital (ROIC) | 45.13% | 45.40% | 25.63% | 20.13% | 23.01% | 27.40% |
Return on Capital Employed (ROCE) | 38.10% | 39.80% | 24.50% | 14.70% | 14.20% | 16.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 5.50% | 4.02% | 2.76% | 1.06% | 1.91% | 1.73% |
FCF Yield | 3.69% | 2.79% | 1.79% | 0.24% | -0.12% | 1.88% |
Dividend Yield | 2.92% | 2.46% | 2.23% | 2.14% | 1.28% | 0.51% |
Payout Ratio | 46.27% | 50.45% | 138.01% | 74.36% | 38.19% | 24.21% |
Buyback Yield / Dilution | 0.19% | -0.37% | -0.60% | -0.95% | -7.46% | 0.31% |
Total Shareholder Return | 3.11% | 2.08% | 1.63% | 1.19% | -6.19% | 0.82% |